Why the study?
Does a novel whole blood agglutination assay accurately measure glycoprotein IIb/IIIa receptor blockade?
Does a novel whole blood agglutination assay accurately measure glycoprotein IIb/IIIa receptor blockade?
A novel, rapid whole-blood assay can effectively monitor the degree of glycoprotein IIb/IIIa receptor blockade, potentially aiding in optimizing antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
May aid preclinical monitoring of GP IIb/IIIa blockade; leaves open clinical validation and utility.
BACKGROUND: The platelet glycoprotein (GP) IIb/IIIa receptor antagonist c7E3 Fab (abciximab; ReoPro) has been approved as an antithrombotic agent, and other GP IIb/IIIa antagonists, including oral agents, are under development. At present, there are no rapid and simple assays to monitor GP IIb/IIIa receptor blockade. METHODS AND RESULTS: An assay was devised based on the ability of platelets in whole blood to rapidly agglutinate fibrinogen-coated beads when stimulated with a peptide, (iso-S)FLLRN, that activates a platelet thrombin receptor but resists inactivation by plasma aminopeptidase M. Preincubation of normal blood with increasing concentrations of c7E3 Fab led to increasing inhibition of the assay, correlating with increased GP IIb/IIIa receptor blockade. Assay conditions were chosen so that agglutination was inhibited at 2 minutes when > 82% of the receptors were blocked. Similar results were obtained with the use of GP IIb/IIIa antagonists based on the arginine-glycine-aspartic acid (RGD) cell-recognition sequence. CONCLUSIONS: A simple and rapid assay sensitive to GP IIb/IIIa receptor blockade has been developed that may be helpful in optimizing GP IIb/IIIa antagonist therapy.
No takes yet. Share an insight, caveat, or question.
Coller et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: